Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMB-05X in Tenosynovial Giant Cell Tumor of the Knee
NCT04731675Phase 2Completed
- Sponsor
- AmMax Bio
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of ABM-05X in tenosynovial giant cell tumor (TGCT), sponsored by AmMax Bio. Started May 2021; status: completed.
02
Drugs
ABM-05X
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04731675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731675.